SHANGHAI, China, August 25, 2022 (GLOBE NEWSWIRE) 鈥 Shanghai Junshi Biosciences Co., Ltd (鈥淛unshi Biosciences鈥? HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that Suzhou Junjing Biomedical Technology Co., Ltd., a company jointly invested by Junshi Biosciences and Wigen Biomedicine Technology (Shanghai) Co., Ltd., has received a notice from the U.S. Food and Drug Administration (the 鈥淔DA鈥? concerning the approval of the investigational new drug (鈥淚ND鈥? application for XPO1 inhibitor WJ01024 tablets (product code: 鈥淛S110鈥? by the FDA. So far, 6 innovative drugs in Junshi Biosciences鈥 pipeline have obtained IN